Esmolol hydrochloride, cardioselective beta-blocker (ab145817)

Overview

  • Product name

    Esmolol hydrochloride, cardioselective beta-blocker
  • Description

    Cardioselective β-blocker, used to control rapid heartbeats or abnormal heart rhythms.
  • Alternative names

    • 4-[2-Hydroxy-3-[(1-methylethyl)amino]propoxy]benzenepropanoic acid methyl ester hydrochloride hydrochloride
    • Brevibloc
    • Esmolol (hydrochloride)
    • Esmolol HCL
    • Methyl 3-{4-[2-Hydroxy-3-(isopropylamino)propoxy]phenyl}propanoate hydrochloride
    see all
  • Biological description

    Ultrashort-acting β1 adrenoceptor antagonist (β1 receptor occupancy = 84.7%); the primary site of activity is on sinus node and atrioventricular (AV) nodal conduction systems. Antiarrhythmic agent.

  • CAS Number

    81161-17-3
  • Chemical structure

    Chemical Structure

Properties

  • Chemical name

    Methyl 3-[4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]propanoate hydrochloride
  • Molecular weight

    331.83
  • Molecular formula

    C16H25NO4.HCl
  • Storage instructions

    Store at -20°C. Store under desiccating conditions. The product can be stored for up to 12 months.
  • Solubility overview

    Soluble in DMSO to 100 mM, in water to 100 mM and in ethanol to 100 mM
  • Handling

    Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.

    Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.

  • Source

    Synthetic

References

This product has been referenced in:

  • Deng CY  et al. Esmolol inhibits Na+ current in rat ventricular myocytes. Methods Find Exp Clin Pharmacol 28:697-702 (2006). Read more (PubMed: 17235414) »
  • Wiest D Esmolol. A review of its therapeutic efficacy and pharmacokinetic characteristics. Clin Pharmacokinet 28:190-202 (1995). Read more (PubMed: 7758250) »
  • Volz-Zang C  et al. Esmolol, an ultrashort-acting, selective beta 1-adrenoceptor antagonist: pharmacodynamic and pharmacokinetic properties. Eur J Clin Pharmacol 46:399-404 (1994). Read more (PubMed: 7957532) »
  • Vucevic M  et al. Esmolol hydrochloride for management of the cardiovascular stress responses to laryngoscopy and tracheal intubation. Br J Anaesth 68:529-30 (1992). Read more (PubMed: 1642945) »
  • Greenspan AM  et al. Electrophysiology of esmolol. Am J Cardiol 56:19F-26F (1985). Read more (PubMed: 2864844) »
  • Yacobi A  et al. Esmolol: a pharmacokinetic profile of a new cardioselective beta-blocking agent. J Pharm Sci 72:710-1 (1983). Read more (PubMed: 6135794) »

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab145817.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES, NOT FOR USE IN HUMANS"
For licensing inquiries, please contact partnerships@abcam.com

Sign up